Relay Therapeutics Analyst Ratings
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $14
JMP Securities Maintains Market Outperform on Relay Therapeutics, Lowers Price Target to $21
Market Outperform Rating Maintained for Relay Therapeutics Amidst Promising Developments of RLY-2608
Maintaining Buy Rating on Relay Therapeutics: Future Catalysts Counterbalance SHP2 Setback
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $18
Relay Therapeutics Analyst Ratings
Barclays Issues a Buy Rating on Relay Therapeutics (RLAY)
Relay Therapeutics Analyst Ratings
Relay Therapeutics (RLAY) Gets a Buy From Barclays
Relay Therapeutics Upgraded by Barclays Ahead of Data Readout
Relay Therapeutics Analyst Ratings
Optimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst Confidence
Relay Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Kura Oncology (KURA)
Barclays Keeps Their Hold Rating on Relay Therapeutics (RLAY)
Strong Buy Rating for Relay Therapeutics Amid Pipeline Progress and Strategic Direction
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Relay Therapeutics (RLAY) and Regeneron (REGN)
Relay Therapeutics (RLAY) Gets a Hold From Barclays
Optimistic Buy Rating for Relay Therapeutics: Strong Financial Standing and Strategic Pipeline Focus